ARTICLE | Distillery Therapeutics
Autoimmune disease
December 13, 2016 8:00 PM UTC
In vitro and mouse studies identified a benzoimidazolylpyridine-based LANCL2 agonist that could help treat IBD. In silico screening of benzoimidazole analogs for LANCL2 binding followed by chemical sy...
BCIQ Target Profiles